6533b833fe1ef96bd129b6f1

RESEARCH PRODUCT

Rapporto costo-efficacia della terapia peginterferone α-2a + ribavirina in confronto a interferone α-2b + ribavirina in pazienti affetti da epatite cronica di tipo C precedentemente non trattati

Neil WintfeldC. De CarliAntonio CraxìJesse GreenAlfredo AlbertiGiovanni GiulianiK. K. PatelK. K. PatelSean D. Sullivan

subject

business.industryHealth PolicyRibavirinvirus diseasesVirologydigestive system diseasesVirological responsechemistry.chemical_compoundchemistryChronic hepatitisInterferonmedicinePharmacology (medical)businessmedicine.drug

description

Introduction In adults with previously untreated chronic hepatitis C (CHC), the combination of peginterferon α-2a plus ribavirin produces a higher rate of sustained virological response (SVR) than interferon α-2b plus ribavirin, but it is still unproven whether this increase is cost-effective. The objective of this study was to determine if the gain in SVR with peginterferon α-2a plus ribavirin is worth the incremental cost.

https://doi.org/10.1007/bf03320628